Renée Henrica Lamberta Raaijmakers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Renée Henrica Lamberta Raaijmakers has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Cornelia Rosanne Maria Ausems
Department of Human Genetics, Radboud University Medical Center, Donders lnstitute for Brain Cognition and Behavior, 6525 GA Nijmegen, the Netherlands
2 shared publications - Derick Gert Wansink
Radboud University Medical Center
2 shared publications - Hans van Bokhoven
Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands
2 shared publications Marieke Willemse
Radboud University Medical Center, Radboud Institute for Medical Innovation, Department of Medical BioSciences, 6525 GA Nijmegen, the Netherlands
2 shared publicationsAlexandra Marrero Quiñones
Center for Inherited Myology Research, Virginia Commonwealth University, Richmond, USA
1 shared publicationBaziel Gerardus Maria van Engelen
Department of Neurology, Radboud University Medical Center, Donders lnstitute for Brain Cognition and Behavior, 6500 HB Nijmegen, the Netherlands
1 shared publication
Latest Publications
- Open Access
- 19 June 2026
- Published by Elsevier in Stem Cell Research
- Vol. 95, 104040
Generation of isogenic rescue iPSC lines by targeted CTG-repeat excision for myotonic dystrophy type 1
- 19 June 2026
- Published by Elsevier in Stem Cell Research
- Vol. 95, 104040
Open AccessGeneration of isogenic rescue iPSC lines by targeted CTG-repeat excision for myotonic dystrophy type 1
- 22 September 2025
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 21 (11) , 623-641
Myotonic dystrophy type 1: clinical diversity, molecular insights and therapeutic perspectives
Myotonic dystrophy type 1 (DM1) is the most prevalent muscular dystrophy in adulthood and is one of the most clinically diverse monogenic diseases. Although it is classified as a neuromuscular disease, DM1 is a multisystem disorder that affects nearly all organ systems, particularly skeletal and smooth muscles, the central nervous system and the heart. Its phenotypic variability extends beyond a continuum of severity, encompassing differences in age of onset and organ involvement. DM1 is caused by a trinucleotide (CTG) repeat expansion within the 3′ untranslated region of the DMPK gene, leading to a toxic RNA gain-of-function mechanism that disrupts RNA splicing, causing widespread cellular dysfunction. Despite progress in understanding DM1 pathogenesis, gaps remain in elucidating genotype–phenotype correlations, genetic modifiers and mechanisms that influence disease progression. Breakthroughs in the past five to ten years have uncovered important insights into the molecular underpinnings of DM1 and accelerated therapeutic innovation. Targeted interventions such as small molecules, antisense oligonucleotides and gene-editing technologies are progressing into clinical trials. Additionally, emerging research on somatic instability, epigenetic modifications and novel biomarkers suggests approaches for precision medicine. This Review synthesizes recent clinical and molecular discoveries, highlighting implications for therapy development. By integrating clinical heterogeneity with mechanistic insights, we provide a framework for future translational research and therapeutic innovation in this life-limiting disease.
- 22 September 2025
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 21 (11) , 623-641
Myotonic dystrophy type 1: clinical diversity, molecular insights and therapeutic perspectives
Myotonic dystrophy type 1 (DM1) is the most prevalent muscular dystrophy in adulthood and is one of the most clinically diverse monogenic diseases. Although it is classified as a neuromuscular disease, DM1 is a multisystem disorder that affects nearly all organ systems, particularly skeletal and smooth muscles, the central nervous system and the heart. Its phenotypic variability extends beyond a continuum of severity, encompassing differences in age of onset and organ involvement. DM1 is caused by a trinucleotide (CTG) repeat expansion within the 3′ untranslated region of the DMPK gene, leading to a toxic RNA gain-of-function mechanism that disrupts RNA splicing, causing widespread cellular dysfunction. Despite progress in understanding DM1 pathogenesis, gaps remain in elucidating genotype–phenotype correlations, genetic modifiers and mechanisms that influence disease progression. Breakthroughs in the past five to ten years have uncovered important insights into the molecular underpinnings of DM1 and accelerated therapeutic innovation. Targeted interventions such as small molecules, antisense oligonucleotides and gene-editing technologies are progressing into clinical trials. Additionally, emerging research on somatic instability, epigenetic modifications and novel biomarkers suggests approaches for precision medicine. This Review synthesizes recent clinical and molecular discoveries, highlighting implications for therapy development. By integrating clinical heterogeneity with mechanistic insights, we provide a framework for future translational research and therapeutic innovation in this life-limiting disease.
- Open Access
- 1 December 2019
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 15, 120-132
Intrinsic Myogenic Potential of Skeletal Muscle-Derived Pericytes from Patients with Myotonic Dystrophy Type 1
- 1 December 2019
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 15, 120-132
Open AccessIntrinsic Myogenic Potential of Skeletal Muscle-Derived Pericytes from Patients with Myotonic Dystrophy Type 1
- Open Access
- 27 July 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (15) , 3689
CRISPR/Cas Applications in Myotonic Dystrophy: Expanding Opportunities
CRISPR/Cas technology holds promise for the development of therapies to treat inherited diseases. Myotonic dystrophy type 1 (DM1) is a severe neuromuscular disorder with a variable multisystemic character for which no cure is yet available. Here, we review CRISPR/Cas-mediated approaches that target the unstable (CTG•CAG)n repeat in the DMPK/DM1-AS gene pair, the autosomal dominant mutation that causes DM1. Expansion of the repeat results in a complex constellation of toxicity at the DNA level, an altered transcriptome and a disturbed proteome. To restore cellular homeostasis and ameliorate DM1 disease symptoms, CRISPR/Cas approaches were directed at the causative mutation in the DNA and the RNA. Specifically, the triplet repeat has been excised from the genome by several laboratories via dual CRISPR/Cas9 cleavage, while one group prevented transcription of the (CTG)n repeat through homology-directed insertion of a polyadenylation signal in DMPK. Independently, catalytically deficient Cas9 (dCas9) was recruited to the (CTG)n repeat to block progression of RNA polymerase II and a dCas9-RNase fusion was shown to degrade expanded (CUG)n RNA. We compare these promising developments in DM1 with those in other microsatellite instability diseases. Finally, we look at hurdles that must be taken to make CRISPR/Cas-mediated editing a therapeutic reality in patients.
- 27 July 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (15) , 3689
Open AccessCRISPR/Cas Applications in Myotonic Dystrophy: Expanding Opportunities
CRISPR/Cas technology holds promise for the development of therapies to treat inherited diseases. Myotonic dystrophy type 1 (DM1) is a severe neuromuscular disorder with a variable multisystemic character for which no cure is yet available. Here, we review CRISPR/Cas-mediated approaches that target the unstable (CTG•CAG)n repeat in the DMPK/DM1-AS gene pair, the autosomal dominant mutation that causes DM1. Expansion of the repeat results in a complex constellation of toxicity at the DNA level, an altered transcriptome and a disturbed proteome. To restore cellular homeostasis and ameliorate DM1 disease symptoms, CRISPR/Cas approaches were directed at the causative mutation in the DNA and the RNA. Specifically, the triplet repeat has been excised from the genome by several laboratories via dual CRISPR/Cas9 cleavage, while one group prevented transcription of the (CTG)n repeat through homology-directed insertion of a polyadenylation signal in DMPK. Independently, catalytically deficient Cas9 (dCas9) was recruited to the (CTG)n repeat to block progression of RNA polymerase II and a dCas9-RNase fusion was shown to degrade expanded (CUG)n RNA. We compare these promising developments in DM1 with those in other microsatellite instability diseases. Finally, we look at hurdles that must be taken to make CRISPR/Cas-mediated editing a therapeutic reality in patients.
- 1 July 2016
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 146-147, 50-59
The anti-absence effect of mGlu5 receptor amplification with VU0360172 is maintained during and after antiepileptogenesis
- 1 July 2016
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 146-147, 50-59
The anti-absence effect of mGlu5 receptor amplification with VU0360172 is maintained during and after antiepileptogenesis